最新一期业绩显示，2025年一季报，公司实现营业收入2.08亿元，同比4.32%；净利润57.38万元，同比 103.06%，销售毛利率37.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14光正眼科-14.05-12.5019.1321.83亿行业平均 38.6644.623.37152.83亿行业中值43.3251.712.6756.60亿1润达医疗-296.69196.342.56108.54亿2何氏眼 科-138.99-120.951.7333.14亿3*ST生物-119.91-116.579.8523.13亿4诚达药业-71.50-122.491.6134.42亿5普 瑞眼科-66.28-59.552.8460.66亿6皓宸医疗-51.14-61.516.0723.18亿7国际医学-44.93-45.183.22114.83亿8创 新医疗-43.20-48.242.5745.32亿9金域医学-34.69-35.521.97135.41亿10百诚医药-33.08-80.771.6742.60亿11 迪安诊断-22.22-24.961.3689.18亿 来源：金融界 5月27日，光正眼 ...

Group 1 - The core viewpoint of the articles highlights the advancement in the diagnosis and treatment of amblyopia through genetic testing and innovative therapies, particularly the use of perceptual learning training [1][2] - The introduction of genetic testing allows for more accurate diagnosis by identifying pathogenic gene mutations, which can lead to more effective treatment strategies [1][2] - The perceptual learning training technique utilizes the brain's plasticity to improve visual processing pathways, enhancing treatment outcomes for patients with amblyopia and related conditions [2] Group 2 - He Eye Hospital has been committed to technological innovation and collaboration with strategic partners to advance eye health, focusing on gene therapy, stem cell regeneration, and smart ophthalmic equipment [3] - The company aims to integrate cutting-edge technology with healthcare data to create a comprehensive ecosystem for eye health, aligning with national health strategies [3] - The strategic goal of He Eye Hospital is to build a "Smart City of Light," leveraging its unique advantages in the eye health industry [3]

庞继景教授指出，基因检测正逐步成为儿童视力评估常规项目，结合屈光矫正形成多维度干预体系。这 种转变使弱视治疗成功率提升30%，并为遗传性眼病患者抢抓3-12岁视觉发育黄金期。 作为国内眼健康全产业链平台，何氏眼科持续深耕基因治疗、干细胞再生医学及智能设备数据应用三大 领域。在"十四五"眼健康规划推动下，企业正通过科技创新践行"智慧光明城"战略目标，为健康中国建 设注入新动能。（燕云） （文章来源：证券时报网） 近日，何氏眼科(301103)在儿童弱视诊疗领域取得突破性进展。通过融合基因检测与视知觉学习训练技 术，成功将传统弱视诊疗模式推向精准化新阶段。 在临床实践中，遗传眼病首席科学家庞继景教授团队接诊的9岁高度近视患儿案例引发关注。通过 OPN1LW基因检测，团队发现其近视实为遗传性视网膜疾病早期表现，颠覆了传统"弱视"诊断结论。基 于此，团队创新采用视知觉学习训练：通过Gabor视标刺激视觉皮层神经可塑性，经4个月家庭化训练， 患儿右眼视力从0.7提升至0.9，屈光度发展得到有效控制。 这项技术的突破性在于构建"基因筛查-大脑重塑"双轨诊疗体系。通过排除致病基因变异确保诊断精准 性，再运用视知觉训练激活视 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301103 证券简称：何氏眼科 公告编号：2025-020 辽宁何氏眼科医院集团股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）回购专用证券账户中的股份2,722,719股不 参与本次权益分派。本次分红派息将以公司现有总股本158,026,471股剔除已回购股份2,722,719股后的 155,303,752股为基数，向全体股东每10股派发现金红利1.5元（含税），实际派发现金分红总额 =155,303,752股×1.5元/10股=23,295,562.80元（含税），不进行公积金转增股本和送红股。 2、本次权益分派实施后计算除权除息价格时，按公司总股本（含回购股份）折算的每10股现金分红 （含税）=现金分红总额÷总股本（含回购股份）×10股=23,295,562.80元÷158,026,471股×10股=1.474155 元/股（保留六位小数，最后一位直接截取，不四舍五入）。 本次权益 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2025-020 辽宁何氏眼科医院集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 账户中的股份 2,722,719 股不参与本次权益分派。本次分红派息将以公司现有总 股本 158,026,471 股剔除已回购股份 2,722,719 股后的 155,303,752 股为基数，向 全体股东每 10 股派发现金红利 1.5 元（含税），实际派发现金分红总额 =155,303,752 股×1.5 元/10 股=23,295,562.80 元（含税），不进行公积金转增股本 和送红股。 【注：根据先进先出的原则，以投资者证券账户为单位计算持股期限，持股 年（含 1 年）的，每 10 股补缴税款 0.150000 元；持股超过 1 年的，不需补缴税 款。】 折算的每 10 股现金分红（含税）=现金分红总额÷总股本（含回购股份）×10 股 =23,295,562.80 元÷158,026,471 股×10 股=1.474155 元/股（保留六位小数，最后一 位直接截取，不四舍五入）。 本次权 ...

Core Insights - The collaboration between Carl Zeiss and He Eye Hospital marks the introduction of advanced refractive surgery technology in Northeast China, providing a revolutionary "10-second rapid vision correction" experience for myopic patients [1][3] - The new generation of all-laser technology, VISUMAX 800 and SMILE pro, offers significant improvements in surgical efficiency, precision, and safety, enhancing patient comfort during procedures [1][2] Group 1: Technology and Innovation - The VISUMAX 800 technology reduces single-eye scanning time from 23 seconds to under 10 seconds, improving efficiency by 36% and minimizing patient discomfort during surgery [1] - The technology features CentraLign intelligent navigation and OcuLign eye rotation compensation systems, which track eye movements in real-time and reduce postoperative residual astigmatism [1] - The dual robotic arm design ensures stable and reliable operation during surgery, enhancing overall safety [1] Group 2: Clinical Application and Experience - He Eye Hospital successfully completed its first SMILE pro surgery on May 15, with the first patient expressing high satisfaction with the quick and nearly painless procedure [2] - The hospital has established a comprehensive service management system, ensuring standardized operations and clinical experience to support the application of this breakthrough technology [2] - He Eye Hospital has been recognized as one of the first high-end refractive surgery institutions in China, emphasizing its commitment to technological innovation and patient-centered care [2] Group 3: Financial Services and Accessibility - The launch of the "Bright Future" financial service plan in collaboration with Industrial Bank provides low-interest installment credit services to myopic patients, making advanced technology more accessible [2]

Core Viewpoint - The company aims to focus on organic growth while completing its mission of external mergers and acquisitions, with a strategic emphasis on the "1+8+N" model and the integration of artificial intelligence in ophthalmology services [2][3]. Financial Performance - In 2024, the company reported a revenue of 20.983 billion yuan, a year-on-year increase of 3.02%, and a net profit exceeding 3.5 billion yuan, growing by 5.87% [2]. - In Q1 2025, the company returned to high growth, achieving a revenue of 6.026 billion yuan, up 15.97%, and a net profit of 1.05 billion yuan, increasing by 16.71% [2]. Strategic Development - The "1+8+N" strategy has been fully implemented, with significant progress in establishing regional ophthalmology centers across China, including flagship hospitals in Shanghai and Nanning [3]. - The company has expanded its operational footprint to 352 ophthalmology hospitals and 229 outpatient departments, enhancing its chain operation advantages [3]. Digital Transformation - The company has made notable advancements in digital ophthalmology and AI applications, collaborating with the Chinese Academy of Sciences to explore the establishment of "Aier AI Eye Hospital" [4]. - The company launched its self-developed ophthalmology vertical model AierGPT and the digital persona "Eyecho," enhancing service efficiency and patient experience [4]. Social Responsibility - The company integrates public welfare into its development strategy, conducting vision health screenings and education in schools and rural areas, and has donated 217 million yuan in 2024 [5]. - The company has established a stable cash dividend system, with a total cash dividend of approximately 1.487 billion yuan for 2024, maintaining a consistent dividend payout for 15 years [5].

核心城市商业地产估值调整，优质物业受到各方青睐。不少主营业务稳健发展的上市公司正加速购入核 心地段写字楼、自持办公或研发用房，以优化资产结构、降低长期经营成本、推进集团化扩张。 《证券日报》记者梳理发现，今年以来，已有多家上市公司公告购置办公楼、研发楼或产业用房，主要 分布于深圳、上海、北京、珠海等一线与重点二线城市。 戴德梁行中国资本市场部董事总经理、联席主管刘兵向《证券日报》记者表示，当前大宗物业交易呈现 区域下沉、买家多元化的显著趋势。北京，上海是交易主战场，但很多省会城市的资产也越来越受到内 资金融机构和本地企业的关注。除了传统的投资机构外，不少能源类企业也通过购置物业实现资产保值 与产业链延伸，而现金流充裕的制造业龙头则借机升级办公载体、整合上下游资源，形成"以产带投、 以投促产"的闭环生态。 年内多家上市公司买楼 5月13日，爱尔眼科（300015）医院集团股份有限公司(以下简称"爱尔眼科")公告称，公司全资子公司 深圳滨海爱尔眼科医院(以下简称"深圳滨海爱尔")通过广东联合产权交易中心，以近6.5亿元价格收购深 圳广晟数码技术有限公司60%股权及特定债权，核心资产包括"广晟科创大厦"，位于深圳南 ...

5月20日，光正眼科今日收盘4.24元，上涨2.17%，最新市净率19.27，创40天以来新低，总市值21.98亿 元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14光正眼科-14.15-12.5919.2721.98亿行业平均 38.4944.343.45153.98亿行业中值39.2651.172.7152.70亿1润达医疗-295.54195.572.55108.11亿2何氏眼 科-141.11-122.801.7633.64亿3*ST生物-124.18-120.7310.2023.96亿4诚达药业-70.53-120.841.5933.96亿5普 瑞眼科-68.23-61.292.9262.44亿6皓宸医疗-51.88-62.406.1623.52亿7国际医学-45.90-46.163.29117.31亿8创 新医疗-45.01-50.262.6847.22亿9金域医学-35.68-36.542.02139.30亿10百诚医药-29.81-72.771.5038.38亿11 迪安诊断-22.78-25.591.4091.43亿 截至2025年一季报，共有3家机构持仓光正眼科，其中其他3家 ...

爱尔眼科董事长陈邦：公司近期暂无港股上市打算 智通财经5月20日电，爱尔眼科董事长陈邦在今日举行的公司2024年度股东大会上，回答投资者"是否考 虑港股上市"的提问时表示，公司近期暂时没有这个打算。他说，"（港股）上市目的主要是筹集资金， 爱尔现在筹资能力很强，现金流也非常不错，银行放贷利息也低，因此近期没有这个打算。关键是看企 业的发展，有特别好的标的，资金能力又不够的话，那可能才会考虑。"（智通财经记者 李拥军） ...